Maze Therapeutics

MAZE · Nasdaq · United States

Share price · MAZE

$31.20+2.07 (+7.11%) 3M

close as of 2026-11-18 · 24h delayed · vol 712K (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MAZE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 22 Sep 2026+26.8%
  2. 9 Sep 2026-6.8%

    Nothing announced by MAZE that day or the session before.

  3. 10 Aug 2026-4.8%

    Nothing announced by MAZE that day or the session before.

  4. 16 Jul 2026-7.6%

    Nothing announced by MAZE that day or the session before.

  5. 25 Mar 2026-35.2%
  6. 10 Mar 2026+13.3%
  7. 20 Jan 2026+8.8%

    Nothing announced by MAZE that day or the session before.

  8. 18 Dec 2025+5.8%

Share of unusual movement by asset

For each asset, the share of MAZE's own-move activity since 3 Feb 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
MZE829
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—13%
Other company news (earnings, financing, releases naming no asset)—26%
Sessions with no dated event—61%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
APOL1 (Apolipoprotein L1)Small molecule
Chronic Kidney Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

25 March 2026Topline resultMZE829Phase 2 HORIZON topline: MZE829 reduced uACR by 35.6% at week 12
Maze Therapeutics · Source ↗

Financial reports

Quarterly & interim (9)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$40M$155M+ $236M short-term inv.$48M-$33M operating cash flowreport ↗
View 8 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$35M$204M+ $208M short-term inv.$45M-$15M operating cash flowreport ↗
2026-Q1$20M$34M$200M+ $154M short-term inv.$24M-$39M operating cash flowreport ↗
2025-Q3—$25M$318M+ $67M short-term inv.$30M-$25M operating cash flowreport ↗
2025-Q2$0$28M$266M$34M-$30M operating cash flowreport ↗
2025-Q1—$28M$295M$33M-$30M operating cash flowreport ↗
2024-Q3$2.5M$20M$151M$25M-$23M operating cash flowreport ↗
2024-Q2$165M$20M$176M—$145M operating cash flowreport ↗
2024-Q1—$22M$31M$32M-$23M operating cash flowreport ↗

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$108M$190M+ $153M short-term inv.$33M-$112M operating cash flowreport ↗

For fiscal 2025, Maze Therapeutics recognized no license revenue, versus $167.5M in 2024, while R&D expense was $108.4M, up 29.9% YoY from $83.5M. Cash, cash equivalents and marketable securities totaled $360.0M at December 31, 2025, compared with $196.8M at the end of 2024. The company reported a net loss of $131.1M for the year, after net income of $52.2M in 2024.

The company announced positive topline data from the Phase 2 HORIZON trial of MZE829, showing a 35.6% mean reduction in uACR at week 12 in broad AMKD patients, and plans to advance MZE829 into a pivotal program while continuing enrollment. Two Phase 2 proof-of-concept trials of MZE782 in PKU and CKD are expected to initiate by mid-2026 and in the second half of 2026, respectively. Maze also appointed Neil Kumar to its board of directors and earned a $20M milestone from Shionogi related to first-patient dosing in the ESPRIT Phase 2 trial of MZE001. Management expects its current cash position to fund operations into 2028.

View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$168M$84M$198M—$76M operating cash flowreport ↗
2023-FY——$30M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 100 sales ($25.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-02Coloma Jason V · director, Chief Executive OfficerOpen-market sale2,257$30.12$68KForm 4
2026-11-02Coloma Jason V · director, Chief Executive OfficerOpen-market sale336$30.91$10KForm 4
2026-11-02Coloma Jason V · director, Chief Executive OfficerOpen-market sale26,563$30.09$799KForm 4
2026-11-02Coloma Jason V · director, Chief Executive OfficerOpen-market sale5,345$31.05$166KForm 4
2026-10-29Dandekar Atul · CSBOOption exercise6,643$10.42$69KForm 4
2026-10-29Dandekar Atul · CSBOOption exercise857$10.42$9KForm 4
2026-10-29Dandekar Atul · CSBOOpen-market sale7,500$32.07$241KForm 4
2026-10-29Dandekar Atul · CSBOOption exercise (derivative)6,643——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 165 reporting institutions held 51.7M shares ($1.5B, 94.5% of shares outstanding).

#InstitutionSharesValue
1Frazier Life Sciences Management, L.P.4,567,274$136.3M
2TRV GP IV, LLC4,473,958$133.5M
3ARCH Venture Management, LLC4,120,053$123.0M
4Deep Track Capital, LP3,477,562$103.8M
5JANUS HENDERSON GROUP PLC2,858,876$85.3M
6Paradigm Biocapital Advisors LP2,744,399$81.9M
7BlackRock, Inc.2,570,425$76.7M
8a16z Capital Management, L.L.C.1,702,225$50.8M
9Venrock Adviser, LLC1,602,034$47.8M
10VANGUARD CAPITAL MANAGEMENT LLC1,435,656$42.9M
11Alphabet Inc.1,388,583$41.4M
12Logos Global Management LP1,235,000$36.9M
13ADAGE CAPITAL PARTNERS GP, L.L.C.1,178,000$35.2M
14General Catalyst Group Management, LLC1,035,910$30.9M
15TRV GP V, LLC950,800$28.4M